Akebia Therapeutics (AKBA) Free Cash Flow Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 39.19% |
| 10 | Akebia Therapeutics | 337.81 Mn | 175.21 Mn | 41.25 Mn | -2.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.56% |
| Dec 31, 2025 | 36.18% |
| Sep 30, 2025 | 5.78% |
| Jun 30, 2025 | 42.65% |
| Mar 31, 2025 | 8.32% |
| Dec 31, 2024 | 60.70% |
| Sep 30, 2024 | 50.86% |
| Jun 30, 2024 | 46.97% |
| Mar 31, 2024 | 33.89% |
| Dec 31, 2023 | 30.39% |
| Sep 30, 2023 | 23.16% |
| Jun 30, 2023 | -44.28% |
| Mar 31, 2023 | 38.97% |
| Dec 31, 2022 | 12.20% |
| Sep 30, 2022 | 40.93% |
| Jun 30, 2022 | 15.19% |
| Mar 31, 2022 | 49.84% |
| Dec 31, 2021 | 5.54% |
| Sep 30, 2021 | -66.27% |
| Jun 30, 2021 | -104.49% |